Transfusion Medicine Reviews
Volume 20, Issue 1 , Pages 45-56 , January 2006

The Role of Photochemical Treatment With Amotosalen and UV-A Light in the Prevention of Transfusion-Transmitted Cytomegalovirus Infections

References 

  1. Mocarski ES. Cytomegalovirus and their replication. In:  Fields BN,  Knipe DM,  Howley PM, et al. editor. Fields virology. Philadelphia: Lippincott-Raven; 1996;p. 2447–2492
  2. Zanghellini F, Boppana SB, Emery VC, et al. Asymptomatic primary cytomegalovirus infection: Virologic and immunologic features. J. Infect. Dis. 1999;180:702–707
  3. Prosch S, Docker WD, Reinke P, et al. Human cytomegalovirus reactivation in bone-marrow–derived granulocyte/monocyte progenitor cells and mature monocytes. Intervirology. 1999;42:308–313
  4. Roback JD. CMV and blood transfusions. Rev. Med. Virol. 2002;12:211–219
  5. Kreel I, Zaroff LI, Canter JW, et al. A syndrome following total body perfusion. Surg. Gynecol. Obstet. 1960;111:317–321
  6. Wilhelm JA, Matter L, Schopfer K. The risk of transmitting cytomegalovirus to patients receiving blood transfusions. J. Infect. Dis. 1986;154:169–171
  7. Bowden RA, Sayers M, Flournoy N, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomegalovirus infection after marrow transplantation. N. Engl. J. Med. 1986;314:1006–1010
  8. Bowden RA, Slichter SJ, Sayers MH, et al. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood. 1991;78:246–250
  9. Bowden RA, Slichter SJ, Sayers M, et al. A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood. 1995;86:3598–3603
  10. Nichols WG, Price TH, Gooley T, et al. Transfusion-transmitted cytomegalovirus infection after receipt of leukoreduced blood products. Blood. 2003;101:4195–4200
  11. Drew WL, Tegtmeier G, Alter HJ, et al. Frequency and duration of plasma CMV viremia in seroconverting blood donors and recipients. Transfusion. 2003;43:309–313[comment]
  12. Roback JD, Drew WL, Laycock ME, et al. CMV DNA is rarely detected in healthy blood donors using validated PCR assays. Transfusion. 2003;43:314–321[comment]
  13. Visconti MR, Pennington J, Garner SF, et al. Assessment of removal of human cytomegalovirus from blood components by leucocyte depletion filters using real-time quantitative PCR. Blood. 2004;103:1137–1139
  14. Dumont LJ, Luka J, VandenBroeke T, et al. The effect of leucocyte-reduction method on the amount of human cytomegalovirus in blood products: A comparison of apheresis and filtration methods. Blood. 2001;97:3640–3647
  15. Corash L. Pathogen reduction technology: Methods, status of clinical trials, and future prospects. Curr. Hematol. Rep. 2003;2:495–502
  16. Wu YY, Snyder EL. Safety of the blood supply: Role of pathogen reduction. Blood Rev. 2003;17:111–122
  17. Wagner SJ, Robinette D, Storry J, et al. Differential sensitivities of viruses in red cell suspensions to methylene blue photosensitization. Transfusion. 1994;34:521–526
  18. Ohagen A, Gibaja V, Horrigan J, et al. Induction of latent human cytomegalovirus by conventional gamma irradiation and prevention by treatment with INACTINE PEN110. Vox Sang. 2004;87:1–9
  19. Lin L. Inactivation of cytomegalovirus in platelet concentrates using Helinx technology. Semin. Hematol. 2001;38:27–33(Suppl 11)
  20. Slobedman B, Mocarski ES. Quantitative analysis of latent human cytomegalovirus. J. Virol. 1999;73:4806–4812
  21. Narvios AB, Lichtiger B. Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: A retrospective study. Haematologica. 2001;86:749–752
  22. Boeckh M, Nichols WG, Papanicolaou G, et al. Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol. Blood Marrow Transplant. 2003;9:543–558
  23. Galea G, Urbaniak SJ. The incidence and consequences of cytomegalovirus transmission via blood transfusion to low birth weight, premature infants in north east Scotland. Vox Sang. 1992;62:200–207
  24. Preiksaitis JK, Sandhu J, Strautman M. The risk of transfusion-acquired CMV infection in seronegative solid-organ transplant recipients receiving non–WBC-reduced blood components not screened for CMV antibody (1984 to 1996): Experience at a single Canadian center. Transfusion. 2002;42:396–402
  25. Murphy MF, Grint PC, Hardiman AE, et al. Use of leucocyte-poor blood components to prevent primary cytomegalovirus (CMV) infection in patients with acute leukaemia. Br. J. Haematol. 1988;70:253–254
  26. Preiksaitis JK, Desai S, Vaudry W, et al. Transfusion- and community-acquired cytomegalovirus infection in children with malignant disease: A prospective study. Transfusion. 1997;37:941–946
  27. Raynor BD. Cytomegalovirus infection in pregnancy. Semin. Perinatol. 1993;17:394–402
  28. Miller WJ, McCullough J, Balfour HH, et al. Prevention of cytomegalovirus infection following bone marrow transplantation: A randomized trial of blood product screening. Bone Marrow Transplant. 1991;7:227–234
  29. Wingard JR, Chen DY, Burns WH, et al. Cytomegalovirus infection after autologous bone marrow transplantation with comparison to infection after allogeneic bone marrow transplantation. Blood. 1988;71:1432–1437
  30. Meyers JD, Flournoy N, Thomas ED. Nonbacterial pneumonia after allogeneic marrow transplantation: A review of ten years' experience. Rev. Infect. Dis. 1982;4:1119–1132
  31. Enright H, Haake R, Weisdorf D, et al. Cytomegalovirus pneumonia after bone marrow transplantation. Risk factors and response to therapy. Transplantation. 1993;55:1339–1346
  32. Forman SJ, Zaia JA. Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: Where do we stand?. Blood. 1994;83:2392–2398
  33. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J. Infect. Dis. 1986;153:478–488
  34. Beschorner WE, Hutchins GM, Burns WH, et al. Cytomegalovirus pneumonia in bone marrow transplant recipients: Miliary and diffuse patterns. Am. Rev. Respir. Dis. 1980;122:107–114
  35. Boyce NW, Hayes K, Gee D, et al. Cytomegalovirus infection complicating renal transplantation and its relationship to acute transplant glomerulopathy. Transplantation. 1988;45:706–709
  36. Wingard JR, Piantadosi S, Burns WH, et al. Cytomegalovirus infections in bone marrow transplant recipients given intensive cytoreductive therapy. Rev. Infect. Dis. 1990;12:S793–S804(Suppl 7)
  37. Ljungman P, Brand R, Einsele H, et al. Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: An EBMT Megafile analysis. Blood. 2003;102:4255–4260
  38. Adler SP, Chandrika T, Lawrence L, et al. Cytomegalovirus infections in neonates acquired by blood transfusions. Pediatr. Infect. Dis. 1983;2:114–118
  39. Preiksaitis JK, Brown L, McKenzie M. Transfusion-acquired cytomegalovirus infection in neonates: A prospective study. Transfusion. 1988;28:205–209
  40. Yeager AS, Grumet FC, Hafleigh EB, et al. Prevention of transfusion-acquired cytomegalovirus infections in newborn infants. J. Pediatr. 1981;98:281–287
  41. Lamberson HV, McMillian JA, Weiner LB, et al. Prevention of transfusion-associated cytomegalovirus (CMV) infection in neonates by screening blood donors for IgM to CMV. J. Infect. Dis. 1988;157:820–823
  42. Gilbert GL, Hayes K, Hudson IL, et al. Prevention of transfusion-acquired cytomegalovirus infection in infants by blood filtration to remove leucocytes. Neonatal Cytomegalovirus Infection Study Group. Lancet. 1989;1:1228–1231
  43. Rubin RH, Tolkoff-Rubin NE, Oliver D. Multicenter seroepidemiologic study of the impact of cytomegalovirus infection on renal transplantation. Transplantation. 1985;40:243–249
  44. Falagas ME, Snydman DR, Griffith J, et al. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. Ann. Intern. Med. 1997;126:275–279
  45. Gorensek MJ, Carey WD, Vogt D, et al. A multivariate analysis of risk factors for cytomegalovirus infection in liver-transplant recipients. Gastroenterology. 1990;98:1326–1332
  46. Falagas ME, Snydman DR, Ruthazer R, et al. Primary cytomegalovirus infection in liver transplant recipients: Comparison of infections transmitted via donor organs and via transfusions. Clin. Infect. Dis. 1996;23:292–297
  47. Preiksaitis JK, Rosno S, Grumet C, et al. Infections due to herpesviruses in cardiac transplant recipients: Role of the donor heart and immunosuppressive therapy. J. Infect. Dis. 1983;147:974–981
  48. Smyth RL, Scott JP, Borysiewicz LK, et al. Cytomegalovirus infection in heart-lung transplant recipients: Risk factors, clinical associations, and response to treatment. J. Infect. Dis. 1991;164:1045–1050
  49. Kovacs A, Schluchter M, Easley K, et al. Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1–infected women. N. Engl. J. Med. 1999;341:77–84
  50. Webster A, Lee CA, Cook DG, et al. Cytomegalovirus infection and progression towards AIDS in haemophiliacs with human immunodeficiency virus infection. Lancet. 1989;2:63–66
  51. Webster A, Phillips AN, Lee CA, et al. Cytomegalovirus (CMV) infection, CD4+ lymphocyte counts and the development of AIDS in HIV-1–infected haemophiliac patients. Clin. Exp. Immunol. 1992;88:6–9
  52. Rabkin CS, Hatzakis A, Griffiths PD, et al. Cytomegalovirus infection and risk of AIDS in human immunodeficiency virus–infected hemophilia patients. J. Infect. Dis. 1993;168:1260–1263
  53. Britt WJ, Alford CA. Cytomegalovirus. In:  Fields BN,  Knipe DM,  Howley PM, et al. editor. Fields virology. Philadelphia: Lippincott-Raven; 1996;p. 2493–2523
  54. Hahn G, Jores R, Mocarski ES. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc. Natl. Acad. Sci. U. S. A. 1998;95:3937–3942
  55. Soderberg-Naucler C, Streblow DN, Fish KN, et al. Reactivation of latent human cytomegalovirus in CD14(+) monocytes is differentiation dependent. J. Virol. 2001;75:7543–7554
  56. Paloheimo JA, von Essen R, Klemola E, et al. Subclinical cytomegalovirus infections and cytomegalovirus mononucleosis after open heart surgery. Am. J. Cardiol. 1968;22:624–630
  57. Henle W, Henle G, Scriba M, et al. Antibody responses to the Epstein-Barr virus and cytomegaloviruses after open-heart and other surgery. N. Engl. J. Med. 1970;282:1068–1074
  58. Prince AM, Szmuness W, Millian SJ, et al. A serologic study of cytomegalovirus infections associated with blood transfusions. N. Engl. J. Med. 1971;284:1125–1131
  59. Preiksaitis JK, Grumet FC, Smith WK, et al. Transfusion-acquired cytomegalovirus infection in cardiac surgery patients. J. Med. Virol. 1985;15:283–290
  60. Preiksaitis JK, Brown L, McKenzie M. The risk of cytomegalovirus infection in seronegative transfusion recipients not receiving exogenous immunosuppression. J. Infect. Dis. 1988;157:523–529
  61. Curtsinger LJ, Cheadle WG, Hershman MJ, et al. Association of cytomegalovirus infection with increased morbidity is independent of transfusion. Am. J. Surg. 1989;158:606–610
  62. Chou S, Kim DY, Norman DJ. Transmission of cytomegalovirus by pretransplant leukocyte transfusions in renal transplant candidates. J. Infect. Dis. 1987;155:565–567
  63. Hutchinson DL, Turner JH, Schlesinger ER. Persistence of donor cells in neonates after fetal and exchange transfusion. Am. J. Obstet. Gynecol. 1971;109:281–284
  64. Adams PT, Davenport RD, Reardon DA, et al. Detection of circulating donor white blood cells in patients receiving multiple transfusions. Blood. 1992;80:551–555
  65. Lee TH, Donegan E, Slichter S, et al. Transient increase in circulating donor leukocytes after allogeneic transfusions in immunocompetent recipients compatible with donor cell proliferation. Blood. 1995;85:1207–1214
  66. Wenk RE, Chiafari PA. DNA typing of recipient blood after massive transfusion. Transfusion. 1997;37:1108–1110
  67. Lee TH, Paglieroni T, Ohto H, et al. Survival of donor leukocyte subpopulations in immunocompetent transfusion recipients: Frequent long-term microchimerism in severe trauma patients. Blood. 1999;93:3127–3139
  68. Sester M, Gartner BC, Sester U, et al. Is the cytomegalovirus serologic status always accurate? A comparative analysis of humoral and cellular immunity. Transplantation. 2003;76:1229–1230
  69. De Witte T, Schattenberg A, VanDijk BA, et al. Prevention of primary cytomegalovirus infection after allogeneic bone marrow transplantation by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors. Transplantation. 1990;50:964–968
  70. Verdonck LF, de Graan-Hentzen YC, Dekker AW, et al. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation. Bone Marrow Transplant. 1987;2:73–78
  71. Eisenfeld L, Silver H, McLaughlin J, et al. Prevention of transfusion-associated cytomegalovirus infection in neonatal patients by the removal of white cells from blood. Transfusion. 1992;32:205–209
  72. Landaw EM, Kanter M, Petz LD. Safety of filtered leukocyte-reduced blood products for prevention of transfusion-associated cytomegalovirus infection. Blood. 1996;87:4910
  73. Ljungman P, Larsson K, Kumlien G, et al. Leukocyte depleted, unscreened blood products give a low risk for CMV infection and disease in CMV seronegative allogeneic stem cell transplant recipients with seronegative stem cell donors. Scand. J. Infect. Dis. 2002;34:347–350
  74. Ronghe MD, Foot AB, Cornish JM, et al. The impact of transfusion of leucodepleted platelet concentrates on cytomegalovirus disease after allogeneic stem cell transplantation. Br. J. Haematol. 2002;118:1124–1127
  75. Zwicky C, Tissot JD, Mazouni ZT, et al. Prevention of post-transfusion cytomegalovirus infection: Recommendations for clinical practice. Schweiz. Med. Wochenschr. 1999;129:1061–1066
  76. Blajchman MA, Goldman M, Freedman JJ, et al. Proceedings of a consensus conference: Prevention of post-transfusion CMV in the era of universal leukoreduction. Transfus. Med. Rev. 2001;15:1–20
  77. Preiksaitis JK. Prevention of transfusion-acquired CMV infection: Is there a role for NAT?. Transfusion. 2003;43:302–305
  78. Roback JD, Hillyer CD, Drew WL, et al. Multicenter evaluation of PCR methods for detecting CMV DNA in blood donors. Transfusion. 2001;41:1249–1257
  79. Stocchi R, Ward KN, Fanin R, et al. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation. Haematologica. 1999;84:71–79
  80. Kocher AA, Bonaros N, Dunkler D, et al. Long-term results of CMV hyperimmune globulin prophylaxis in 377 heart transplant recipients. J. Heart Lung Transplant. 2003;22:250–257
  81. Guglielmo BJ, Wong-Beringer A, Linker CA. Immune globulin therapy in allogeneic bone marrow transplant: A critical review. Bone Marrow Transplant. 1994;13:499–510
  82. Lin L, Cook DN, Wiesehahn GP, et al. Photochemical inactivation of viruses and bacteria in platelet concentrates by use of a novel psoralen and long-wavelength ultraviolet light. Transfusion. 1997;37:423–435
  83. Knutson F, Alfonso R, Dupuis K, et al. Photochemical inactivation of bacteria and HIV in buffy-coat–derived platelet concentrates under conditions that preserve in vitro platelet function. Vox Sang. 2000;78:209–216
  84. Grass JA, Hei DJ, Metchette K, et al. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood. 1998;91:2180–2188
  85. Ciaravino V. Preclinical safety of a nucleic acid–targeted Helinx compound: A clinical perspective. Semin. Hematol. 2001;38:12–19
  86. van Rhenen DJ, Vermeij J, Mayaudon V, et al. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sang. 2000;79:206–214
  87. van Rhenen D, Gulliksson H, Cazenave JP, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: The euroSPRITE trial. Blood. 2003;101:2426–2433
  88. Hambleton J, Wages D, Radu-Radulescu L, et al. Pharmacokinetic study of FFP photochemically treated with amotosalen (S-59) and UV light compared to FFP in healthy volunteers anticoagulated with warfarin. Transfusion. 2002;42:1302–1307
  89. Jordan CT, Saakadze N, Newman JL, et al. Photochemical treatment of platelet concentrates with amotosalen hydrochloride and ultraviolet A light inactivates free and latent cytomegalovirus in a murine transfusion model. Transfusion. 2004;44:1159–1165

 None of the authors received any financial or other support from third parties for the work described in this manuscript. The expert panel roundtable presentations and discussion, described in this article, were supported by Baxter Transfusion Therapies. Dr Conlan is affiliated with and has stocks or stock options in Cerus Corporation.

PII: S0887-7963(05)00081-7

doi: 10.1016/j.tmrv.2005.08.004

Transfusion Medicine Reviews
Volume 20, Issue 1 , Pages 45-56 , January 2006

Article Tools

* Image Usage & Resolution